Patents Examined by Lorraine Spector
  • Use of inhibitors for the treatment of RTK-hyperfunction-induced disorders, particularly cancer
    Patent number: 7678372
    Abstract: The invention provides a method for the therapeutic treatment of a cancer in a mammal wherein (i) the mammal comprises a mutated fibroblast growth factor receptor-4 (FGFR-4) protein, and (ii) the mutated FGFR-4 comprises at least one point mutation in the transmembrane domain of FGFR-4 that substitutes a hydrophilic amino acid for a hydrophobic amino acid. The method comprises administering to the mammal an effective amount of at least one inhibitor of the mutated FGFR-4.
    Type: Grant
    Filed: August 27, 2003
    Date of Patent: March 16, 2010
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.
    Inventors: Axel Ullrich, Johannes Bange, Pjotr Knyazev
  • Method for diagnosing insulin resistance from nasal secretions
    Patent number: 7670849
    Abstract: The invention is directed to a method of detecting a biological substance in the nasal secretion and diagnosing a disease following the detection of the biological substance wherein the biological substance is not related to a respiratory disease. The invention also provides treatment of the diseases following the detection of the biological substance and/or diagnosis of the disease. In some embodiments, the diseases are cancer, hepatitis, smell loss, taste loss, diabetes, and leprosy. The invention also provides a kit for diagnosing a disease. The present invention includes methods of analyzing samples from the nose for the detection of biological substances. In particular, nasal secretion or nasal mucus is collected and analyzed for biological substances. The results of this analysis are then suitable for use in diagnosis, prognosis, and determination of suitability of therapeutic interventions.
    Type: Grant
    Filed: May 1, 2006
    Date of Patent: March 2, 2010
    Inventor: Robert I. Henkin
  • Liquid growth hormone formulation and method of use
    Patent number: 7662393
    Abstract: The invention relates to a liquid formulation comprising a growth hormone or a substance, which stimulates release or potentiates the activity of endogenous hGH; a polyethylene-polypropylene glycol; a citrate/phosphate buffer, an alkali metal salt and an alkaline earth metal salt or a pseudo alkaline earth metal salt, and to a process of preparation thereof.
    Type: Grant
    Filed: March 30, 2005
    Date of Patent: February 16, 2010
    Assignee: Ares Trading S.A.
    Inventors: Tudor Arvinte, Karnine Luet Kleiber
  • Method of preventing ? cell disruption in pancreatic Langerhans' islets
    Patent number: 7662366
    Abstract: The object of the present invention is to provide a method for treating diabetes which is simple, safe and effective when compared to conventional diabetes treatment. The administration of one or more stem cell-recruiting factors allows a simple and safe repair of disrupted ?-cells in pancreatic Langerhans' islets. Thus, the therapeutic agent of the present invention which comprises one or more stem cell-recruiting factors as active ingredients is useful for diabetes treatment. Examples of such a stem cell-recruiting factor include colony-stimulating factors such as G-CSF.
    Type: Grant
    Filed: April 15, 2004
    Date of Patent: February 16, 2010
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yoshiki Kawabe, Yuichiro Adachi
  • Compositions and methods of preparation of liposomal microparticulate IL-12
    Patent number: 7662405
    Abstract: This invention provides methods and compositions for localized delivery of IL-12 to a desired site. The composition comprises liposomes carrying IL-12. The liposomes comprise phosphatidyl choline, phosphatidyl glycerol and cholesterol. The size and composition of the liposomes is such that there is minimal leakage into the systemic circulation. These compositions can be used for delivery of IL-12 to selected sites such as tumors.
    Type: Grant
    Filed: August 9, 2006
    Date of Patent: February 16, 2010
    Assignee: The Research Foundation of State University of New York
    Inventors: Sathy V. Balu-Iyer, Richard B. Bankert, Vivek S. Purohit
  • Method of inhibiting the activity of growth factor homolog ZVEGF3
    Patent number: 7658920
    Abstract: Polypeptide growth factor ZVEGF3, methods of making it, polynucleotides encoding it, antibodies that bind to it, and methods of using them are disclosed. The polypeptide comprises an amino acid segment that is at least 90% identical to residues 46-163 of SEQ ID NO:2 or residues 235-345 of SEQ ID NO:2. Multimers of the polypeptide are also disclosed. The polypeptide, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents. The antibodies may be used to inhibit cell growth.
    Type: Grant
    Filed: October 24, 2006
    Date of Patent: February 9, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Zeren Gao, Charles E. Hart, Christopher S. Piddington, Paul O. Sheppard, Kimberly E. Shoemaker
  • Implantable device for continuous delivery of interferon
    Patent number: 7655254
    Abstract: An implantable device includes a reservoir containing a suspension of an interferon in an amount sufficient to provide continuous delivery of the interferon at a therapeutically effective rate of 1 ng/day to 600 ?g/day to maintain and achieve therapeutic blood or plasma levels of the interferon throughout a substantial period of the administration period.
    Type: Grant
    Filed: February 3, 2006
    Date of Patent: February 2, 2010
    Assignee: Intarcia Therapeutics, Inc.
    Inventors: Paula Dennis, Michael A. Desjardin, Stan Lam, Kui Liu, James E. Matsuura, Latha Narayanan, Catherine M. Rohloff, Pauline C. Zamora
  • Variants of human glycoprotein hormone alpha chain: compositions and uses thereof
    Patent number: 7655781
    Abstract: The present invention provides human glycoprotein hormone (hGPH) ?-chain splice variants, including isolated nucleic acids encoding these variants and the encoded amino acid sequences, as well as antibodies, antisense oligonucleotides, expression vectors and host cells comprising these sequences. The present invention further discloses the use of these sequences in the diagnosis, prevention and treatment of symptoms, diseases and disorders related to glycoprotein hormones.
    Type: Grant
    Filed: May 5, 2006
    Date of Patent: February 2, 2010
    Assignees: Compugen Ltd., Protalix Ltd.
    Inventors: Ronen Shemesh, Jeanne Bernstein, Dvir Dahary, Gil Shalev, Gideon Baum, Yoseph Shaaltiel
  • Therapeutic calcium phosphate particles and methods of making and using same
    Patent number: 7651694
    Abstract: The present invention provides calcium phosphate nano-particles encapsulated with biologically active macromolecules. The particles may be used as carriers of biologically active macromolecule for delivery of the macromolecules. The invention also provides methods of making and using the particles.
    Type: Grant
    Filed: February 11, 2005
    Date of Patent: January 26, 2010
    Assignee: NOD Pharmaceuticals, Inc.
    Inventor: William W. Lee
  • Monoclonal antibodies against interleukin-22
    Patent number: 7638604
    Abstract: Antibodies and antigen-binding fragments thereof that bind interleukin-22 (IL-22), in particular, human IL-22, and their uses in regulating IL-22-associated immune responses are disclosed. The antibodies disclosed herein are useful in diagnosing, preventing, or treating IL-22-associated immune disorders, e.g., autoimmune disorders (e.g., arthritis).
    Type: Grant
    Filed: June 22, 2004
    Date of Patent: December 29, 2009
    Assignee: Genetics Institute, LLC
    Inventors: Jing Li, Xiang-Yang Tan, Kathleen N. Tomkinson, Debra D. Pittman, Geertruida M. Veldman, Lynette Fouser
  • BAFF receptor antibodies and methods
    Patent number: 7638327
    Abstract: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: December 29, 2009
    Assignee: Biogen IDEC MA Inc.
    Inventors: Christine M. Ambrose, Jeffrey S. Thompson
  • BAFF receptor polypeptides
    Patent number: 7635677
    Abstract: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: December 22, 2009
    Assignee: Biogen IDEC MA Inc.
    Inventors: Christine M. Ambrose, Jeffrey S. Thompson
  • Protease resistant mutant of human HMGB1 high affinity binding domain Box-A (HMGB1 Box-A)
    Patent number: 7635679
    Abstract: The present invention relates to polypeptide variants of the HMGB-1 high affinity binding domain Box-A (HMGB1 Box-A) or to a biologically active fragment of HMGB1 Box-A, which are obtained through systematic mutations of single amino acids of the wild-type HMGB1 Box-A protein and which show an increased resistance to proteases and which are therefore characterized by more favorable pharmacokinetic and pharmacodynamic profiles. Moreover, the present invention concerns the use of said polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and associated with RAGE.
    Type: Grant
    Filed: March 5, 2007
    Date of Patent: December 22, 2009
    Assignee: Creabilis Therapeutics S.p.A.
    Inventors: Silvano Fumero, Luisa Bertarione Rava Rossa, Domenico G. Barone, Lila Drittanti, Thierry Guyon, Gilles Borrelly, Barbara Canepa, Chiara Lorenzetto
  • Estrogen receptor genes and utilization thereof
    Patent number: 7629138
    Abstract: An estrogen receptor gene and utilization of the estrogen receptor gene. The estrogen receptor gene contains a nucleotide sequence coding for any of the following amino acid sequences: (a) the amino acid sequence of SEQ ID NO:1, (b) the amino acid sequence of SEQ ID NO:4, (c) the amino acid sequence of SEQ ID NO:23, (d) an amino acid sequence exhibiting 95% or more amino acid identity to the amino acid sequence of SEQ ID NO:1, (e) an amino acid sequence exhibiting 95% or more amino acid identity to the amino acid sequence of SEQ ID NO:4, and (f) an amino acid sequence exhibiting 85% or more amino acid identity to the amino acid sequence of SEQ ID NO:23.
    Type: Grant
    Filed: June 27, 2008
    Date of Patent: December 8, 2009
    Assignee: Sumitomo Chemical Company Limited
    Inventor: Koichi Saito
  • NF-?B activating gene
    Patent number: 7629453
    Abstract: Provided are proteins having NF-?B activity, which are used for diagnosing, treating or preventing diseases associated with the excessive activation or inhibition of NF-?B. Using plasmid pNF ?B-Luc, cDNA encoding a protein capable of activating NF-?B has been cloned from a cDNA library constructed from human lung fibroblasts, and the DNA sequence and the deduced amino acid sequence determined. The protein, the DNA encoding the protein, a recombinant vector containing the DNA, and a transformant containing the recombinant vector are useful for screening a substance inhibiting or promoting NF-?B activation.
    Type: Grant
    Filed: January 8, 2007
    Date of Patent: December 8, 2009
    Assignee: Asahi Kasei Pharma Corporation
    Inventors: Akio Matsuda, Goichi Honda, Shuji Muramatsu, Yukiko Nagano
  • Cystine-knot fold protein
    Patent number: 7619065
    Abstract: This invention relates to a novel protein (INSP002), herein identified as a secreted protein that is a member of the Dan family of the cystine-knot fold cytokine superfamily and to the use of this protein and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease.
    Type: Grant
    Filed: June 21, 2004
    Date of Patent: November 17, 2009
    Assignee: Ares Trading S.A.
    Inventors: Mark Douglas Davies, Christopher Benjamin Phelps, Richard Joseph Fagan, Christine Power, Melanie Yorke, Mark Ibberson
  • Methods of detecting cancer with antibodies to cytokine receptor ZCYTOR19
    Patent number: 7618791
    Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor19, a novel class II cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor19, are located on chromosome 1p36.11, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: October 6, 2006
    Date of Patent: November 17, 2009
    Assignee: ZymoGenetics, LLC
    Inventor: Theodore E. Whitmore
  • Protease resistant modified interferon alpha polypeptides
    Patent number: 7611700
    Abstract: Processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided is a rational method for generating protein variants and the resulting variants.
    Type: Grant
    Filed: September 8, 2003
    Date of Patent: November 3, 2009
    Assignee: Hanall Pharmaceuticals, Co., Ltd.
    Inventors: Rene Gantier, Manuel Vega, Lila Drittanti, Thierry Guyon
  • Polynucleotides encoding cytokine receptor zcytor19
    Patent number: 7608452
    Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor19, a novel class II cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor19, are located on chromosome 1p36.11, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: October 27, 2009
    Assignee: ZymoGenetics, LLC
    Inventors: Scott R. Presnell, Theodore E. Whitmore, Francis J. Grant, Emily C. Costerison
  • Method of screening for agents that modulate Tysnd1 level or activity in a cell.
    Patent number: 7605005
    Abstract: The invention relates to a pharmaceutical composition for treating or diagnosing a disorder associated with production of peroxisome in a cell, comprising a polypeptide which has cysteine protease activity and directly processes peroxisomal enzymes targeted by PTS1 or PTS2 signals. Preferably, the polypeptide is encoded by Tysnd1.
    Type: Grant
    Filed: December 10, 2007
    Date of Patent: October 20, 2009
    Assignees: Riken, Saitama Medical University
    Inventors: Igor Kurochkin, Christian Schoenbach, Yasushi Okazaki